GlassScriptPhysician profile
Emily Elbogen
NPI 1508357724
$49,364.22
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,517 · 2022: $21K · 2023: $26K · 2024: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $17K · Consulting Fee: $7,200 · Food and Beverage: $2,071 · Travel and Lodging: $812 · Education: $68.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $16,506.00 |
| Consulting Fee | $7,200.00 |
| Food and Beverage | $2,071.21 |
| Travel and Lodging | $811.85 |
| Education | $68.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $22,390.72 | 2021-2023 | Sotyktu |
| Janssen Scientific Affairs, LLC | $6,911.33 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $5,168.71 | 2021-2023 | Siliq, Targretin |
| Janssen Biotech, INC. | $4,446.72 | 2021-2023 | Tremfya |
| Eli Lilly and Company | $2,100.00 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $1,786.87 | 2021-2023 | Dupixent |
| Genzyme Corporation | $1,198.30 | 2021-2023 | |
| Abbvie INC. | $1,189.51 | 2021-2023 | |
| Lilly USA, LLC | $933.20 | 2021-2023 | Taltz |
| Sun Pharmaceutical Industries INC. | $765.24 | 2021-2023 | Ilumya |
| Dermavant Sciences, INC. | $490.10 | 2022-2023 | Vtama |
| Ucb, INC. | $404.98 | 2021-2022 | |
| Incyte Corporation | $403.74 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $335.86 | 2021-2024 | |
| Pfizer INC. | $232.71 | 2021-2024 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $206.08 | 2022-2023 | Adbry |
| Boehringer Ingelheim Pharmaceuticals, INC. | $137.89 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $127.00 | 2024 | Saphnelo |
| Csl Behring | $85.80 | 2022 | |
| Genentech USA, INC. | $18.04 | 2022 | |
| Galderma Laboratories, L.P. | $17.96 | 2022 | |
| Amgen INC. | $13.46 | 2024 | Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Elbogen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.